Physician profile
Nicole A Mitchell
NPI 1639474059
$5,031.99
in general payments reported to CMS, 2019-2025
27 companies · $895 in 2025
The $895 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $232 · 2022: $562 · 2023: $2,395 · 2024: $947 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,154 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,154.28 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,062.33 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $834.68 | 2021-2025 | |
| Celgene Corporation | $450.68 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $408.52 | 2022-2024 | Stelara |
| Pfizer INC. | $331.82 | 2021-2025 | |
| Genzyme Corporation | $229.45 | 2023-2025 | |
| Qol Medical, LLC | $223.33 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $161.81 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $155.07 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $141.22 | 2024 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $132.80 | 2023-2025 | Entyvio |
| Ironwood Pharmaceuticals, INC | $129.38 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $127.29 | 2025 | Voquezna |
| Beigene USA, INC. | $109.45 | 2023 | Brukinsa |
| Merck Sharp & Dohme LLC | $97.46 | 2021-2024 | Dificid, Zinplava |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $71.80 | 2022-2025 | Gimoti |
| Fresenius Kabi USA, LLC | $65.07 | 2023 | Idacio |
| Daiichi Sankyo INC. | $52.55 | 2022-2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $43.76 | 2023 | |
| Intercept Pharmaceuticals, INC. | $43.74 | 2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $36.25 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $25.76 | 2023 | Kristalose |
| Amgen INC. | $25.50 | 2022 | |
| Gilead Sciences, INC. | $23.81 | 2023 | |
| Glaxosmithkline, LLC. | $18.06 | 2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $15.37 | 2025 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $15.03 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.